Efficacy and Safety Comparison of Upadacitinib and Vedolizumab in Second-line Treatment for Crohn's Disease
CompletedOBSERVATIONAL
Enrollment
172
Participants
Timeline
Start Date
January 1, 2020
Primary Completion Date
March 31, 2024
Study Completion Date
March 31, 2024
Conditions
Crohn Disease
Trial Locations (1)
510655
the Sixth Affiliated Hospital of Sun Yat-Sen University, Guangzhou
All Listed Sponsors
lead
Sixth Affiliated Hospital, Sun Yat-sen University
OTHER
NCT06446219 - Efficacy and Safety Comparison of Upadacitinib and Vedolizumab in Second-line Treatment for Crohn's Disease | Biotech Hunter | Biotech Hunter